Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CLNN
CLENE INC.
NASDAQ
$4.23
▼ DOWN 5.37% (-0.24)

KEY STATISTICS

Market Cap$54.05 M
52w High$13.50
52w Low$3.88
Dividend Yield—
Frequency—
P/E-1.19
Volume59.66K
Shares Out.12.78M

COMPANY

LEADERSHIP

Robert Etherington
CHIEF EXECUTIVE
Robert Etherington

COMPENSATION 2026

Salary$508,763
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$38,480
Total$933,394

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 18, 2018
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
78

PRICE TARGET

Target High$50.00
Target Low$50.00
Target Median$50.00
Target Consensus$50.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$70.00K
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2024-07-11Reverse1:20

PRICE

$4.23 ▼ DOWN 5.37% (−$0.24)
OVERLAYS
$4.20$4.35$4.509:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM4.23

About Clene Inc.

https://clene.com ↗

Clene Inc. is a clinical-stage pharma company developing nanotechnology-based therapeutics, including CNM-Au8 for neurodegenerative diseases, infectious diseases, and oncology, with ongoing and planned clinical trials across multiple indications.

INDUSTRY

Biotechnology

A PRODUCT CLENE INC. IS KNOWN FOR

CNM-Au8
CNM-Au8

CNM-Au8, developed by Clene, is a late-stage investigational oral gold nanocrystal suspension targeting neurodegenerative diseases like ALS, MS, and Parkinson's by enhancing mitochondrial health, with plans for accelerated FDA approval for ALS.

COMPETITORS

COMPETITOR
AMLX COMPARE
BCLI COMPARE
BIIB COMPARE
MNOV COMPARE

Revenue by Products

IconPRODUCTQ1-2025Q4-2025Q1-2026Q2-2026
Product$64K $55K ▼$1K ▼$74K ▲
Royalty$17K $64K ▲$14K ▼$16K ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
11
LISTED HERE
2
RANKED BY POSITION SIZE
VTS.AX
0.00% · 231.1K
IWC
0.01% · 30.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
13.80%
HOLDERS
43
TOP 12 OF 43 · RANKED BY POSITION SIZE
Boxer Capital Management, LLC
477.5K sh · $2.35M
Scoggin Management LP
300.0K sh · $1.48M
Ensign Peak Advisors, Inc
257.9K sh · $1.27M
Vanguard Group Inc
222.9K sh · $1.31M
Morgan Jess S & Co Inc
112.0K sh · $314K
Geode Capital Management, LLC
95.9K sh · $473.04K
Blackrock Inc.
83.5K sh · $29.73K
Lunt Capital Management, Inc.
52.3K sh · $257.64K
Peak6 LLC
50.0K sh · $246.56K
Parametric Portfolio Associates LLC
40.0K sh · $158K
Parsons Capital Management Inc/Ri
37.2K sh · $224.39K
Blackrock, Inc.
33.9K sh · $198.71K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
Kiernan Matthew
Purchase · 3.2K shares
2026-08-13
★
DIRECTOR
Desai Arjun JJ
Purchase · 3.7K shares
2026-08-13
★
DIRECTOR
Mosca Alison
Purchase · 4.9K shares
2026-08-13
★
DIRECTOR
MATLIN DAVID J
Purchase · 6.2K shares
2026-08-13

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
4 GRADES IN THE LAST 12 MONTHS
D. Boral Capital BUY HC Wainwright & Co. BUY Canaccord Genuity BUY Benchmark BUY

SECTORS PEERS

PEERPRICE
STTK$7.04COMPARE
OVID$2.80COMPARE
ZNTL$3.80COMPARE
WHWK$4.62COMPARE
MGNX$4.13COMPARE
ORMP$5.03COMPARE
CNTB$2.23COMPARE
COYA$4.59COMPARE